Its roles Owner Operator Developer
Orano Med is a clinical-stage biotechnology subsidiary of the Orano Group focused on developing targeted alpha therapies for cancer using the radioisotope lead-212. The company conducts independent and partnered programs, including collaborations with Sanofi, Roche and Molecular Partners. It maintains research, development and manufacturing capabilities in France and the United States, with a new headquarters and scientific centre opened in Villejuif, France, in 2026.
Orano Med is constructing the Advanced Thorium Extraction Facility in Bessines-sur-Gartempe, France, the first industrial-scale plant dedicated to thorium-228 production as a precursor for lead-212 therapies. In 2026 the European Investment Bank provided a €125 million credit line to support this infrastructure and related expansion.
chemXplore tracks 1 project involving Orano Med, of which one is active.
Funds will build the Advanced Thorium Extraction Facility to scale thorium‑228 supply for lead‑212 targeted alpha therapies and feed ATLabs.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
